It has to be mentioned that immunotherapy has further improved the therapeutic effect of NPC, for example, combination of PD-1/PD-L1 inhibitors with antiangiogenic inhibitor with molecular targeted agents, cancer vaccines, adaptive immunotherapy, and new ICI agents beyond PD-1/PD-L1 inhibitors in R/M NPC [24]. The gene discussed is CD274; the disease is cancer.